WUR works on ‘all-in-one’ vaccine against Ebola and Marburg

Researchers at Wageningen University & Research (WUR) are contributing to the development of a new vaccine designed to provide broad protection against several deadly filoviruses, such as Ebola and Marburg. WUR’s researchers are part of an international team led by Danish biotech company AdaptVac. The project has secured over €10.5 million in funding from CEPI - a public–private partnership for accelerated vaccine development - and Horizon Europe, the European Union’s funding programme.

“We aim to develop a single vaccine that protects high-risk groups, such as healthcare workers, against multiple filoviruses in one go,” says Wageningen virologist Gorben Pijlman. “Filoviruses are among the deadliest viruses in the world and can trigger catastrophic epidemics. An allinone filovirus vaccine would represent a major breakthrough.”  

Within the project, WUR will generate several vaccine candidates. Other partners will then assess their safety and immunogenicity - the vaccine’s ability to stimulate the immune system to protect the body against the virus. WUR previously collaborated with AdaptVac on a COVID-19 vaccine, which in clinical trials was found to be safe and effective. 

More information 

Visit the website.